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Thereisincreasingevidencesupportingtheroleofmembersofthepolycombgroup(PcG)genefamilyintumordevelopmentand
progression. However, their precise role in tumorigenesis and mechanisms of their regulation remain to be elucidated. Using
nasopharyngeal carcinoma (NPC) as a disease model, a comprehensive analysis was undertaken on the clinical signiﬁcance of
EZH2 expression, identiﬁcation of the cellular processes regulated by EZH2, and the mechanisms of its deregulated expression.
Herein, we report EZH2 as being associated with a higher risk of relapse in NPC patients (P¼0.002). Genome-wide microarray
and bioinformatics identiﬁed several vital cellular processes (such as differentiation, development, and apoptosis) to be
regulatedbyEZH2,corroboratedbyinvitro lethality,anddelayedtumorformationinvivouponEZH2depletion.Thecombination
ofglobal microRNA(miR)proﬁling inprimary NPCspecimens,andinsilico analysesprovidedseveral candidatemiRsthat could
regulate EZH2. Using a luciferase-based assay, miR-26a, miR-101, and miR-98 were validated as bona ﬁde regulators of EZH2
expression. In particular, miR-98 was underexpressed in relapsed patient samples, strongly suggesting an important role for the
miR-98 and EZH2 axis in NPC biology.
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There is increasing evidence supporting the role for members
of the polycomb group (PcG) family in tumor development
and progression.
1–3 The PcG family of genes mediates their
function by the formation of several multimeric polycomb
repressive complexes (PRCs) PRC1,PRC2,PRC3,orPRC4.
4
In embryonic and adult stem cells,PcG genesmaintaincellular
identity by repressing transcription of key developmental
genes, such as homeobox genes, and preventing senescence
through repression of the INK4A locus.
5,6 EZH2histonemethyl
transferase, a member of the PcG family, is the catalytic
subunit of the PRC2, which is responsible for methylating
lysine-27 on histone-3. This epigenetic modiﬁcation of H3 is
necessary for gene repression through the PRC2 complex.
7 In
different systems, PRC2 and PRC1 appear to cooperatively
mediate gene silencing.
8 Although more is known about the
functionofPcGfamilyduringdevelopment,theirrolesinhuman
malignancies continue to evolve.
MicroRNAs (miRs) are endogenous 19–25 nucleotide non-
coding RNAs, which regulate gene expression in a sequence-
speciﬁc manner. Since their initial identiﬁcation in the early 90s,
miRs are now increasingly recognized to be key regulators of
gene expression in several biological systems, including
cancer.
9 The current understanding is that miRs regulate gene
expression by mediating mRNA target degradation and
inhibition of translation (reviewed in Calin GA et al.
10)
Nasopharyngeal carcinoma (NPC) represents a subset of
head and neck epithelial cancers, treated by radiation therapy
for early disease, but combined with chemotherapy for more
advanced stages. Despite progress in NPC management, a
signiﬁcant proportion of patients still develop distant meta-
stases, underscoring the need for an improved understanding
of the molecular mechanisms underlying therapy failure. We
have recently reported that overexpression of BMI-1, another
member of the PcG family, mediated radiation resistance
through repression of P53 and reactive oxygen species
(ROS)-dependent apoptosis.
11 In this study, the clinical signi-
ﬁcance of EZH2 in NPC was also determined, along with its
mechanisms in driving NPC progression, and ﬁnally, its own
regulation, in the context of miRs.
Results
Overexpression of EZH2 is associated with poor clinical
outcome in NPC. Our previous microarray expression
proﬁling study on NPC demonstrated overexpression of
EZH2,
12 an observation which was followed up in the current
study using immunohistochemistry. EZH2 protein expression
was, hence, assayed in an independent collection of 39
archival NPC specimens (cohort ‘A’), demonstrating tumor
nuclear immunostaining (Figure 1a). Using a relative scoring
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EZH2 overexpression was observed to associate with a
higher probability of relapse (Figure 1b, P¼0.002). This
overexpression translated into reduced survival wherein the
5-year actuarial probability of overall survival was 45% for
high EZH2 expressors versus 82% for low expressors, using
a median expression value of 10 as the cutoff (Figure 1c,
P¼0.01). In the EBV-positive NPC cell line C666-1, which
provides the NPC in vitro and in vivo model for the
subsequent studies, strong nuclear expression of EZH2
was also observed (Figure 1d).
Targeted depletion of EZH2 is lethal to C666-1 NPC
cells. Given its apparent role in NPC progression, EZH2
was evaluated for its function in NPC cell survival. To this
end, EZH2 was knocked down using small interference RNA
(siRNA), which resulted in reduced EZH2 expression at
both the transcript and the protein levels (Figures 2a and b),
associated with decreased cell viability (Figure 2c). Cyto-
toxicity was further increased when cells were exposed to
ionizing radiation (IR) (Figure 2c, right panel). To conﬁrm
that the cytotoxicity was speciﬁcally attributable to EZH2
depletion, and not to off-target effects, these experiments
were repeated using a previously described siRNA duplex
targeting EZH2,
2 demonstrating a similar reduction in cell
viability (Supplementary Figure 1A). A similar level of
cytotoxicity was observed when EED was also depleted;
EED being a second component of the PRC2 complex,
corroborating the importance of PcG genes in maintaining
survival of NPC cells (Supplementary Figure 1B). Using
combination index analysis,
13 a more than additive inter-
action was observed between EZH2 depletion and IR
(Figure 2d). Then we sought to determine if forced expres-
sion of EZH2 could protect normal cells from IR-induced cell
death. Overexpression of EZH2 did not confer radiation
resistance in normal oral epithelial (data not shown) cells,
hence suggesting that the role of EZH2 in radiation sensitivity
is context dependent and is mainly restricted to tumor cells.
EZH2 depletion induces apoptosis in C666-1 cells. Cell
cycle analysis demonstrated that EZH2-depletion in C666-1
cells led to a signiﬁcant increase in apoptosis (sub-G0), an
increase in G1, and a decrease in the S–G2M phases of
the cell cycle (Figure 3a). Concordantly, apoptosis was
associated with caspase 3/7 activation observed as early as
24h post-transfection (Figure 3b). Given the observed
interaction between EZH2 depletion and IR, the kinetics of
DNA double-strand break (dsb) formation was assessed,
using g-H2AX staining, a commonly utilized marker for dsb.
14
Indeed, an increase in dsb was observed with EZH2
depletion alone, which was further increased on IR expo-
sure (Figure 3c), although the rate of g-H2AX reduction
following IR was not affected by EZH2 depletion, indicating
that EZH2 does not have an apparent role in dsb repair.
Figure 1 Overexpression of EZH2 is associated with poor clinical outcome in NPC (a) Representative immunohistochemical staining demonstrating expression of EZH2
(arrow) in the nuclei of NPC cells. (b) EZH2 is expressed at signiﬁcantly higher levels in relapsed NPC compared with nonrelapsed patient tumors (cohort ‘A’). (c) Kaplan–
MeierplotofoverallsurvivalinthesamecohortasafunctionofEZH2expression,usingthemedianscoreofZ10(high)versuso10(low).(d)Immunoﬂuorescenceoverlayof
EZH2 (red) and nuclear (blue) staining demonstrating nuclear expression of EZH2 in C666-1 cells
Signiﬁcance and regulation of EZH2 expression in NPC
NM Alajez et al
2
Cell Death and DiseaseNPC cells depleted of EZH2 exhibited delayed tumor
growth in vivo. To assess whether targeting EZH2 has an
effect in vivo, C666-1 cells were transfected with siEZH2 as
single agent or combined with IR (4Gy), before implanting into
SCID mice. This resulted in a signiﬁcant reduction in tumor
formation in which no tumors were observed for 25 days in the
siEZH2-treated cells, which was delayed until 31 days when
siEZH2 depletion was combined with IR (Figure 3d), suggest-
ing a potential therapeutic role for targeting EZH2.
Multiple pathways are affected by EZH2 depletion. To
determine the pathways mediating cytotoxicity post-EZH2
depletion, with or without IR (4Gy), microarray analyses
were conducted comparing C666-1 cells transfected with
siEZH2 versus scrambled siRNA at 72h. Not surprisingly,
several hundred genes were differentially expressed (up and
down) post-siEZH2 transfection (Figure 4a, Supplementary
Tables 1 and 2). The changes in expression of 10 selected
transcripts were validated using individual quantitative real-
time PCR (qRT-PCR) (Figure 4b). Pathway and functional
annotation analyses performed on these differentially
expressed genes in EZH2-depleted cells (both siEZH2 and
siEZH2 plus IR) revealed signiﬁcant enrichment for genes
involved in cell differentiation, development, and apoptosis
(Figure 4c). These data are consistent with our observed
induction of apoptosis in EZH2-depleted cells (Figures 3a
and b), and with the established roles for PcG genes in
regulating cell differentiation and development.
15 To conﬁrm
that these differentially expressed genes were indeed
mediating the observed consequences of EZH2 knock
down, BCL2, and FOXM1, which were down regulated upon
EZH2 depletion, were individually targeted using siRNA.
Following BCL2 and FOXM1 depletion in C666-1 cells, the
same cell cycle changes of increased apoptosis, increased
G1, and decreased populations in S–G2M were recapitulated
as with siRNA targeting EZH2 (comparing Figure 4d with left
panel of Figure 3a). Thus, these data corroborate that
downregulation of BCL2 and FOXM1 participate in the cell
cycle changes subsequent to siEZH2. Interestingly, when we
looked for differentially expressed genes between siEZH2 plus
RT and siEZH2 alone, we observed a cluster of genes, which
is involved in the response to DNA damage and DNA repair
(Supplementary Figure 2), thus supporting our conclusion of
the involvement of EZH2 in this process. Other relevant path-
ways include those involved in response to oxidative stress
(Supplementary Table 3); hence Trolox, a commonly utilized
antioxidant was evaluated to determine whether it could
rescue C666-1 cells from cell death post-EZH2 depletion.
Indeed, pretreatment with Trolox led to a signiﬁcant reduction
in apoptosis following EZH2 depletion (Figure 4e), hence
conﬁrming that ROS were produced subsequent to EZH2
depletion, and thereby mediating cytotoxicity.
Identiﬁcation of miR-26a, 98, and 101 as negative
regulators of EZH2. The precise molecular mechanism(s)
leading to EZH2 overexpression in NPC remains unknown.
To focus on the role of miRs in this process, three commonly
utilized miR target prediction algorithms (TargetScan, PicTar,
Figure 2 EZH2 is important for survival of NPC cells in vitro.( a) Reduction in EZH2 transcript level after transfection with siRNA (40nM) targeting EZH2 relative to cells
transfected with scrambled siRNA (40nM), evaluated at 72h post-transfection. The data are presented as mean ± S.E. from two independent experiments, n¼6;
***Pr0.0005. (b) Western blot for EZH2 protein expression, also evaluated at 72h post-transfection with siRNA targeting EZH2. (c) EZH2 depletion signiﬁcantly reduced
C666-1cellviabilityatdays4andday6post-transfection,whichisfurtherenhancedbyIR(4Gy).Thedataarepresentedasmean±S.E.fromtwoindependentexperiments,
n¼6; ***Pr0.0005; ****Pr0.00005. (d) Combination index analysis demonstrating more than additive interaction between EZH2 depletion and IR
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Cell Death and Diseaseand MiRanda) were interrogated for possible interactions
with EZH2. The intersection of these three algorithms
identiﬁed six potential miR candidates: miR-101, 138, 217,
26a, 26b, and 98 (Figure 5a). The expression of these six
miRs was then evaluated in 15 human NPC biopsy
specimens (cohort ‘B’), demonstrating that miR-26a, 26b,
and 101 were all consistently downregulated, compared with
normal nasopharyngeal epithelial tissues, although their
expression levels did not associate with clinical outcome
(Figure 5b). Interestingly however, miR-98 was signiﬁcantly
underexpressed in relapsed versus nonrelapsed NPC
samples (P¼0.05); hence, these four miRs (miR-26a, 26b,
101, and miR-98) were examined in further detail.
Exogenous expression of miR-26a, 98, and 101 caused
cytotoxicity associated with downregulation of EZH2.
We then sought to determine whether overexpressing these
four miRs could mimic the phenotypic changes observed with
Figure 3 EZH2 depletion induced apoptosis in C666-1 cells and delayed tumor growth in vivo.( a) C666-1 cells were transfected with siCtrl (40nM) or siEZH2 (40nM),
then exposed to IR (4Gy) on day 3; cell cycle analyses were conducted on day 4 post-transfection. Data are presented as the mean ± S.E. from two independent
experiments, n¼6; *Pr0.05; **Pr0.005; ***Pr0.0005. (b) Caspase 3/7 activity was measured at 24, 48, and 72h post-transfection with the same siRNAs as in (a). Data
arepresentedasthemean±S.E.fromtwoindependentexperiments,n¼4;*Pr0.05;***Pr0.0005.(c)C666-1cellsweretransfectedwiththesamesiRNAsasin(a),then
exposedto IR(4Gy)at48h post-transfection.Theproportionofg-H2AXexpressingcellswas measuredat theindicatedtimepoints.Dataare presentedasthemean±S.E.
fromtwoindependentexperiments,n¼2.(d)C666-1cellsweretransfectedwithsiCtrl(40nM),orsiEZH2(40nM)for72h,thenexposedtoIR(4Gy),followedbyimplantation
inSCIDmiceon day6 post-transfection.Tumorgrowthwasthenmonitoredovertime.Thedataarepresentedasmean± S.E.foreachgroupofmice,eachgroupconsisting
of 6 mice. Two-way ANOVA analysis was utilized to compare the difference in tumor growth between the indicated groups. *Pr0.05; ***Pr0.0005
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Cell Death and DiseaseEZH2 depletion. Exogenous expression of miR-26a, 98, and
101 all led to signiﬁcant toxicity in C666-1 cells, which
increased with the addition of IR, whereas overexpression of
miR-26b had no effect (Figure 5c). To further determine
whether the three remaining miRs were regulating EZH2,
qRT-PCR was utilized to measure EZH2 mRNA expression
after transfection with miR-26a, 98, and 101. Indeed,
signiﬁcant reduction in EZH2 transcript levels was observed
for all three miRs (Figure 5d). miR-101 has previously
been described to regulate EZH2 expression in prostate
cancer;
16 hence, we sought to determine whether the two
novel miRs (miR-26a and miR-98, which have not been
Figure 4 Genome-wide microarray and pathway analyses reveal multiple pathways regulated by EZH2 in NPC. (a) Venn diagram showing the number of differentially
expressed genes in cells depleted of EZH2 in the presence or absenceof IR. C666-1 cells were transfected with siCtrl (40nM) or siEZH2 (40nM) for 48h, then exposed to IR
(4Gy). RNA was extracted at 72h post-transfection, then hybridized onto the Human Genome U133 Plus 2.0 Array. (b) A representative set of 10 differentially expressed
genesvalidatedusingindividualqRT-PCR,performedat72hpost-transfectionwithsiEZH2(40nM),comparedwithcellstransfectedwithsiCtrl(40nM).Dataarepresentedas
mean ± S.E. from two independent experiments, n¼6. (c) Heatmap displaying enrichment for genes involved in different cellular processes in EZH2-depleted cells; green
color denotes association; black color denotes absence of association with the indicated cellular processes. (d) C666-1 cells were transfected with 40nM of siCtrl, siBLC2, or
siFOXM1, then cell cycle analyses were conducted at 72h post-transfection. The proportion of cells in each stage of the cell cycle is indicated. Data are presented as
mean±S.E. from two independent experiments compared with cells transfected with siCtrl, n¼4; *Pr0.05; **Pr0.005; ***Pr0.0005. (e) C666-1 cells were transfected
withsiEZH2(40nM),thentreatedwithTrolox(500mMonday1and500mMonday2).At2haftersecondTroloxtreatment,halfofthecellswerethenexposedto4GyIR,and
the percent of apoptosis was measured using ﬂow cytometry on day 3. The data are presented as mean ± S.E. from two independent experiments, compared with DMSO-
treated conditions, n¼4; *Pr0.05
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Cell Death and Diseasepreviously described to regulate EZH2 in solid tumors)
regulated EZH2 at the protein level. As shown in Figure 5e,
overexpression of miR-26a or miR-98 reduced EZH2
protein expression, corroborating the biological effects of
these two miRs in regulating EZH2 in NPC. Nonetheless,
an inverse relationship between miR-98, miR-26a, and
EZH2 expression was observed in the FaDu and UTSCC-8
cell lines (Supplementary Figure 3). Knocking down
miR-26a only led to signiﬁcant increase in EZH2 expres-
sion in the FaDu cell line (Supplementary Figure 4),
presumably because of its higher basal level expression in
those cells.
The 30-UTR of EZH2 transcript is a direct target for
miR-26a, 98. To demonstrate the direction interaction of
miR-26a or miR-98 with EZH2, the 30-UTR of EZH2 was
cloned downstream of the ﬁreﬂy luciferase gene in the
pMIR-REPORT vector (with the predicted binding sites for
the miR-26a and miR-98 indicated (Figure 6a)). miR-26a, or
miR-98 were individually co-transfected with pMir-REPORT-
EZH2 UTR, leading to signiﬁcant reduction in luciferase
activity compared with cells transfected with control miR
or pMir-REPORT control vector (Figure 6b). Mutating
the seed region for miR-26a and miR-98 binding in the
pMIR-REPORT-EZH2 UTR vector completely abrogated its
regulatory activity (Figure 6b), thereby conﬁrming that
miR-26a and miR-98 directly interacted with the 30-UTR of
EZH2. We then sought to determine the relative expression
levels of EZH2 and miR-98 in an independent collection of
NPC samples (cohort ‘C’). It was gratifying to observe an
inverse relationship between EZH2 and miR-98 expression
(Figure 6c), thereby supporting the notion of EZH2 regulation
by miR-98 in NPC, although such relationship was less
observed at the single specimen level.
Figure 5 Negative regulation of EZH2 expression by miR-26a, 98, and 101. (a) Venn diagram showing the miRs that were predicted by all three databases (TargetScan,
MiRanda, and PicTar), which can potentially regulate EZH2. (b) Fold change in miR-26a, 26b, 98, and 101 expression in 10 recurrent and 6 nonrecurrent primary NPC
specimens compared with normal nasopharyngeal epithelial tissues (normalized to 1, on a log scale), evaluated in cohort ‘B’. (c) MTS viability for C666-1 cells on day 6 post-
transfection with the indicated miRs (40nM). IR (4Gy) was delivered 24h post-transfection. The data are presented as mean ± S.E. from two independent experiments,
n¼8; *Pr0.05; **Pr0.005; ***Pr0.0005. (d) qRT-PCR analysis of the fold-change in EZH2 mRNA expression 72hrs post-transfection with the indicated miRs (all using
40nM).Dataare presentedas mean± S.E. fromtwoindependentexperiments, n¼6; *Pr0.05;**Pr0.005;***Pr0.0005.(e)Westernblot analysisfor EZH2expression
in C666-1 cells at 72h post-transfection with the indicated pre-miRs; E/G: ratio of EZH2/GAPDH
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Cell Death and DiseaseDiscussion
Although several reports in the literature documented over-
expression of EZH2 in human malignancies, the precise role
of EZH2 in tumorigenesis and the molecular mechanisms
leading to its overexpression remain largely unknown. In this
study, a comprehensive analysis of EZH2 was conducted,
startingwithitspotential clinical valueinNPC, determiningthe
cellular processes regulated by this gene, and documenting
a mechanism leading to its overexpression. The in vitro
experiments demonstrated that EZH2 promote survival of
NPC cells in that its targeted depletion led to cytotoxicity,
mediated by apoptosis and delayed progression through the
cell cycle, translating into delayed tumor growth in vivo
(Figure 3). These data are consistent with reports in the
literature describing similar effects of EZH2 depletion in other
cancer models.
17,18
EZH2 is located on chr7q36.1, which is not a common site
ofchromosomalgaininNPC.
19Thus,alternatemechanism(s)
accounting for EZH2 overexpression was sought, focusing on
miRs, which are increasingly recognized as a major class of
regulatory molecules, by targeting mRNAs for degradation,
and inhibiting protein translation. Using a combinatorial
approach of miR expression proﬁling, bioinformatics, and
biochemical tools, we demonstrated that miR-26a, 98, and
101, which are also underexpressed in NPC, could negatively
regulate EZH2 (Figures 5b and 6). These ﬁndings corroborate
recent reports of miR-26a in regulating EZH2 in Burkitt’s
lymphoma,
20 and miR-101 targeting EZH2 in prostate
cancer.
16 In NPC, however, at least three miRs are shown
Figure 6 EZH2 30-UTR isa directtarget of miR-26a,98, and101. (a) Schematicrepresentation of thepMIR-REPORT-EZH2UTR expression vector with thealignmentof
the indicated miRs with the EZH2 30-UTR with the seed region highlighted in blue (miR), and red (UTR). (b) Percent luciferase activity at 48h post-transfection with the
indicated miR (100nM), and reporter plasmid (100ng). Data are presented as mean ± S.E. from two independent experiments, n¼4; *Pr0.05; **Pr0.005. (c) Inverse
expression ofEZH2(n¼89) with miR-98(n¼99)isobservedinprimaryNPCspecimens(cohort‘C’),asmeasuredbyqRT-PCRandpresentedasfold-changeexpression in
tumors compared with normal nasopharyngeal epithelial tissues (n¼6). ***Pr0.0005. (d) A proposed model derived from these data, illustrating that underexpression of
miR-26a, 98, and 101 lead to upregulation of EZH2, which in turn mediates several important cellular processes all driving the survival of NPC cells; (OS: oxidative stress)
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Cell Death and Diseasehere to target EZH2; speciﬁcally, miR-98 is a novel negative
regulator of EZH2, whose functional signiﬁcance is under-
scored by its downregulation in recurrent NPC (Figure 5b),
consistent with overexpression of EZH2 associating with poor
survival (Figure 1b and c).
Genome-wide microarray analyses revealed that several
hundred genes are either up- or downregulated following
EZH2 depletion, suggesting a dual role for EZH2 in both
silencing and activating transcription (Figure 4a and Supple-
mentary Tables 1 and 2). The latter might appear paradoxical
given that PcG genes are normally viewed as mediators
of gene repression; however, there is increasing evidence
that PcG genes can also mediate transcription, possibly
through long-distance chromosomal interactions.
17,21 Among
the downregulated genes following EZH2 depletion were
FOXM1 and BCL2, which we had previously reported to
be upregulated in primary biopsy samples of NPC,
12 which
one might speculate could relate to EZH2. Functional
analyses documented that FOXM1 and BCL2 indeed
mediated the phenotypic changes of apoptosis and cell cycle
changes, mimicking the same alterations as observed in
EZH2-depleted cells.
Multiple other processes are also affected by EZH2, such
as cellular response to oxidative stress, in which pretreatment
of C666-1 cells with the antioxidant Trolox protected against
cell death induced by EZH2 depletion (Figure 4e). A related
observation has been reported by both ourselves, and others,
whereby BMI-1, another member of the PcG family, has a
role in maintaining ROS homeostasis in both cancer and
normal cells).
11,22,23 Hence, it would appear that PcG genes,
such as BMI1 and EZH2, participate in ROS regulation in
mammalian cells.
In conclusion, our data are the ﬁrst to document that EZH2
expression could serve as a potential prognostic marker for
NPC, and its overexpression mediates several important
cellular processes, all resulting in promoting survival (see
Figure 6d). In addition, miR-26a, 98, and 101 can all regulate
EZH2 expression, with miR-98 perhaps being its most
functionally signiﬁcant negative regulator.
Materials and Methods
Patient samples. In total, 39 formalin-ﬁxed and parafﬁn-embedded (FFPE)
NPC patient biopsy samples were selected for immunohistochemical analysis of
EZH2 from an archival bank of materials as previously described (cohort ‘A’).
24
These patients have all been treated with curative intent, using IR for early-stage
disease, or combined with chemotherapy for locally advanced disease, at the
Princess Margaret Hospital (PMH) during the period of 1985–1992. Owing to
insufﬁcient tissue materials from cohort ‘A’, global miR expression proﬁling was
conductedon 15additionalNPCsamplestreatedsimilarlyat PMHduring theperiod
of 1993–2000 (cohort ‘B’). A third cohort ‘C’ was then utilized to examine the
correlation between EZH2 and miR-98 expression. All tissues utilized in this study
have received institutional REB approval.
Immunohistochemical detection of EZH2 expression. EZH2
immunohistochemistry analysis was evaluated on 4-mm FFPE tumor sections
using microwave antigen retrieval, in combination with the LSABþSystem-HRP
(Dako North America, Carpinteria, CA, USA). Detection of EZH2 utilized rabbit anti-
EZH2 antibody (dilution 1/1000; Invitrogen, Corp., Carlsbad, CA, USA). EZH2
expression was scored using a previously published protocol for EGFR,
25 in which
a score was assigned by combining the percentage of cells with positive EZH2
staining (0–5), with the intensity of staining (1þ to 3þ). Any multiplied values
Z10 were scored as high EZH2 expression.
Quantitative real-time PCR. QRT-PCR analyses were performed using the
ABI PRISM 7900 Sequence Detection System (Applied Biosystems Inc., Foster
City, CA, USA). The primer sequences used in this study are listed in Table 1. To
assesstheefﬁciencyofEZH2knockdown,C666-1cellsweretransfectedwith40nM
siEZH2 or siCtrl, and at indicated time points, cells were collected, and total RNA
was isolated using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). Reverse
transcription wasperformedusingSuperScriptIIIReverseTranscriptase(Invitrogen
Corp.) according to the manufacturer’s recommendations. The relative fold change
in RNA expression was calculated using the 2
 DDCt method, where the average of
DCt values for the amplicon of interest was normalized to that of an endogenous
gene (GAPDH), compared with control specimens. Global miR expression and
single-well miR PCR were conducted as previously described.
26
Cell culture and transfection. The EBV-positive C666-1 NPC cell line
27
was maintainedinRPMI 1640supplementedwith 10%fetalbovineserum,100mg/l
penicillin, and 100mg/l streptomycin (RPMI-10) at 371C and 5% CO2. SMARTpool
siRNAstargetingEZH2,EED,BCL2,andFOXM1werepurchasedfromDharmacon
(Dharmacon Inc., Lafayette,CO, USA). Control siRNAswere purchasedfrom either
Dharmacon or Ambion (Ambion, Austin, TX, USA). miR precursors (pre-miR) were
purchased from Ambion. Locked nucleic acid probes containing sequence-speciﬁc
antisense oligonucleotides targeting miR-26a and miR-98 were purchased from
Exiqon (Exiqon Inc., Vedbaek, Denmark). C666-1 cells were transfected with the
indicated siRNA or pre-miR using the Lipofectamine RNAiMAX (Invitrogen) reverse
transfection protocol, according to the manufacturer’s instructions. At 48 or 72h
post-transfection, cells were exposed to IR (4Gy).
Immunoblotting . C666-1 cells were transfected with 40nM siEZH2, siCtrl,
pre-miR-26a, pre-miR-98, or pre-miR-Ctrl; at 72h post-transfection, cells were
collected and lysed in 1M Tris-HCl (pH 8), 5M NaCl, and 1% NP40 plus protease
inhibitor cocktail (Roche Diagnostics, Quebec, Canada). Protein concentration was
determined using the Bio-Rad Detergent-Compatible Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA). In total, 20mg of protein were loaded onto 10%
Tris-glycine protein gels (Invitrogen) for electrophoresis. The protein was then
transferred onto a nitrocellulose membrane using a Trans-Blot SD Semi-Dry
Transfer Cell (Bio-Rad) and blocked using TBST (0.1% Tween-20 plus 5% fat-free
dry milk). The membrane was probed with anti-EZH2 monoclonal antibody (clone
AC22, 1:1000 dilution, Cell Signaling Technology Inc., Danvers, MA, USA) and
anti-GAPDH antibody (Abcam, Cambridge, MA, USA).
Cell viability and measurement of apoptosis. Cell viability was
assessed using the soluble tetrazolium salt (MTS) cell proliferation assay as
previously described,
28 as these cells are not amenable to clonogenic assays.
Brieﬂy, 20ml of the MTS reagent (Promega, Madison, WI, USA) was added to each
well in a 96-well plate at the indicated time points, and absorbance was measured
at l492. To measure the fraction of cells in the sub G0–G1 phase of the cell cycle,
cells were collected and washed twice in FACS buffer (PBS/0.5% BSA). Cells were
resuspended in 1ml of FACS buffer, and then 3ml of ice-cold 70% ethanol was
addedtoﬁxthecellsfor1honice.Cellswerewashedonce,beforeresuspendingin
500ml of FACS buffer containing 40mg/ml RNAse A (Sigma, St. Louis, MO, USA)
and 50mg/ml propidium iodine. Cells were incubated at room temperature for
30min in the dark before being analyzed in BD FACScalibur (Becton Dickinson,
San Jose, CA, USA) using FL-2A and FL-2W channels. FACS data were analyzed
using FlowJo 7.5 software (Tree Star, San Carlos, CA, USA).
Caspase activation was measured using Promega Apo-ONE Homogeneous
Caspase-3/7 assay. Brieﬂy, cells were transfected with siCtrl or siEZH2, and 48h
later, exposed to 4Gy IR. At indicated time points, caspase 3/7 substrates were
added according to the manufacturer’s speciﬁcations. Plates were analyzed using
SPECTRAFluor Plus Fluorometer (Tecan, Research Triangle Park, NC, USA) at
excitation and emission wavelengths of 485 and 535nm, respectively.
Quantitation of phosphorylated H2AX (c-H2AX). A total of 50000
C666-1 cells were transfected with 40nM siEZH2 or siCtrl, and 48h later, exposed
to IR (4Gy). Staining for g-H2AX was conducted as previously described.
11 Both
attached and detached C666-1 cells were collected at the indicated time points
post-IR, pelleted by centrifugation, washed in FACS buffer (PBS/0.5% BSA), ﬁxed
with 3ml 70% ethanol, and maintained at  201C. After collecting all samples, cells
werepelletedby centrifugation, andrehydratedwith1ml coldTBS(pH 7.4)plus 4%
FBS, and 0.1% Triton X-100 (TST) on ice for 10min. Cells were then centrifuged
and resuspended in 200ml of FITC-labeled mouse monoclonal antiphosphorylated
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Cell Death and Disease(Ser139) histone H2AX antibody (1:500 dilution in TST, clone JBW301, Upstate
Biotechnology Inc., Lake Placid, NY, USA) for 2h at room temperature. Cells were
then washed twice in TBS and analyzed using BD FACScalibur.
Tumor formation. All animal experiments were conducted in accordance with
the guidelines of the Animal Care Committee, University Health Network. For tumor
formation assays, 5 10
4 C666-1 cells were transfected with 40nM siEZH2 or
siCtrl. At 72h later, where indicated, cells were exposed to 4Gy IR using a
137Cs
unit (Gamma-cell 40 Extractor; Nordion International, Inc., Ontario, Canada) at a
dose rate of 1.1Gy per min. On day 6, cells were collected, resuspended in 100ml
PBS, then injected intramuscularly into the left gastrocnemius of 6–8-week-old
female SCID mice. Tumor volume was calculated as described before
29 using the
formula(n¼p d
3/6), whered is thediameterof leg plus tumorand volumeswere
correctedbysubtractingthevolumeofnontumor-bearingleg.Micewerekilledwhen
the humane end point was reached.
Microarrayandbioinformaticsanalyses. C666-1cellsweretransfected
with40nMsiEZH2orsiCtrl,andat48hpost-transfectionhalfofthetransfectedcells
wereexposedtoIR(4Gy).TotalRNAwasextractedfromﬁvetransfectionreplicates
of irradiated and nonirradiated cells 17h post-IR using the Qiagen RNeasy kit
(Qiagen)accordingtothemanufacturer’sinstruction,andtestedforqualityusingthe
Agilent2100Bioanalyzer(AgilentTechnologiesInc.,PaloAlto,CA,USA).Extracted
RNA was labeled and hybridized onto the Affymetrix GeneChip Human Genome
U133 Plus 2.0 array (Affymetrix, Inc., Santa Clara, CA, USA). All procedures
were conducted at the University Health Network Microarray center (Toronto, ON,
Canada). The raw data were normalized using the GCRMA package of the
Bioconductor open source library
30 for R (version 2.7.1) software. Only genes with
‘present’ calls demonstrating a Ztwo-fold change in expression over lipofectamine
and siCtrl-transfected cells were included in the analysis. Heatmaps were
generated using Microsoft excel 2007 (Microsoft, Inc., Redmond, WA, USA).
Gene overlap was assessed using the gene list Venn diagram tool
Table 1 Primer sequences used for cloning and qRT-PCR
No. Name Sequence
1 EZH2
FWD 50-GCGCGGGACGAAGAATAATCAT-30
REV 50-TACACGCTTCCGCCAACAAACT-30
2 ANXA1
FWD 50-GAGATTTTCGGAACGCTTTG-30
REV 50-GCTTCTGGTGGTAAGGATGG-30
3 SMAD6
FWD 50-TGCAACCCCTACCACTTCA-30
REV 50-ATTCACCCGGAGCAGTGAT-30
4 METTL7A
FWD 50-CTGATGGCTCTGTGGATGTG-30
REV 50-TTCCAAGTCGAACACTCAGC-30
5 HMOX1
FWD 50-CCAGGCAGAGAATGCTGAGT-30
REV 50-GTAGACAGGGGCGAAGACTG-30
6 TP53INP1
FWD 50-CCTCCAACCAAGAACCAGAA-30
REV 50-TGCCGGTAAACAGGAAAAGA-30
7 CCND1
FWD 50-CGTGGCCTCTAAGATGAAGG-30
REV 50-CTGGCATTTTGGAGAGGAAG-30
8 FOXM1
FWD 50-AACCTGCAGCTAGGGATGTG-30
REV 50-AGCCCAGTCCATCAGAACTC-30
9 BCL2
FWD 50-GAGTTCGGTGGGGTCATGT-30
REV 50-ACAGTTCCACAAAGGCATCC-30
10 EIF5A2
FWD 50-TCCAGCACTTACCCTATGCAG-30
REV 50-TGCCCGTGAAAATATCAATTC-30
11 HELLS
FWD 50-GCAATGGTTGAACAACTGGA-30
REV 50-ACGGTACCGAATTTCTGTCG-30
12 EZH2
UTR FWD 50-GTTGTTACTAGTCATCTGCTACCTCCTCC-30
UTR REV 50-GTTGTTAAGCTTACAAGTTCAAGTATTCTTTATTC-30
13 EZH2
UTR REV miR-26a MUT 50-GTTGTTAAGCTTACAGAGGAGGGTATTCTTTATTCAAA-30
14 EZH2
UTR FWD miR-98 MUT 50-GTTGTTACTAGT CATCTGACCAACAATCCC CCCTCCTCTGAAC
ACAACGC CTTAAACCAC GGAACCTCGA GTACTGTGGG-30
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Cell Death and Disease(http://mcbc.usm.edu/genevenn/genevenn.htm) Pathway analyses of differentially
expressedgeneswereperformedusingDAVIDBioinformatics Databasefunctional-
annotation tools (http://david.abcc.ncifcrf.gov/).
31
Inhibition of reactive oxygen species. C666-1 cells were transfected as
described above, and at 24 and 48h post-transfection, the antioxidant Trolox
(Sigma) was added at 500mM concentration (from stock solution of 500mM in
DMSO). At 2h following the second Trolox treatment on day 2, cells were exposed
to 4Gy IR. Cells were collected on day 3, ﬁxed in 70% ethanol, then stained and
analyzed to measure the apoptotic fraction as described above.
Luciferase assay. EZH2 30-UTR region was ampliﬁed using the indicated
primers in Table 1, and using AmpliTaq gold DNA polymerase (Applied
Biosystems). The PCR product was then puriﬁed, digested with SpeI and HindIII,
then cloned downstream of the ﬁreﬂy luciferase gene in the pMIR-REPORT vector
(Ambion).A separatevectorcarryingEZH230-UTRwithmutationintheseedregion
for miR-26a or miR-98 was also constructed using the indicated primers in Table 1.
At 72h before transfection, 1 10
5 C666-1 cells were seeded in a 24-well plate.
Cells were then transfected with 100nM of pre-miR-ctrl, 26a, 98, or 101, and 6h
later, cells were co-transfected with 100ng of pMIR-REPORT or pMIR-REPORT
EZH2 30-UTR, along with 50ng of pRL-TK vector (Promega) carrying the Renilla
luciferase gene. Transfection experiments were conducted using Lipofectamine
2000 (Invitrogen). At 48h later,luciferase activity was measured using the Dual-Glo
luciferase assay system (Promega). Fireﬂy luciferase activity was then normalized
to that of Renilla luciferase.
Statistical analysis. Statistical analyses and graphing were performed using
MicrosoftexcelandGraphPadPrismsoftware(GraphPadsoftware,SanDiego,CA,
USA),respectively.Outlierswere removedfrom datausingtheextremestudentized
deviate method (http://www.graphpad.com/quickcalcs/Grubbs1.cfm).
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